Head of R&D Riikka Havunen was awarded oral presentation “Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies” at the 16th Cancer Immunotherapy Annual Meeting in Mainz, Germany in May 2018.
Poster of the presentation was also presented in the meeting.